Effects of metformin on head and neck cancer: A systematic review

Rêgo, Daniela Fortunato; Pavan, Ludmila Madeira Cardoso; Elias, Silvia Taveira; Canto, Graziela De Luca; Guerra, Eliete Neves Silva

doi:10.1016/j.oraloncology.2015.01.007

Cited by 68 publications

(65 citation statements)

References 58 publications

(91 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Consistent with our results, recent population studies reinforced the use of metformin to reduce cancer-related mortality in different types of cancer: head and neck cancer, 21,22 lung cancer, 23e25 breast cancer, 26,27 gastrointestinal cancer, 28e31 gynaecological cancer 32,33 and prostate cancer. 34,35 Other retrospective studies report less encouraging results and only tentative conclusions of the true effect of metformin can be drawn.…”

Section: Discussionsupporting

confidence: 91%

Can metformin improve ‘the tomorrow’ of patients treated for oesophageal cancer?

Voorde

Janssen

Larue

et al. 2015

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 91%

Can metformin improve ‘the tomorrow’ of patients treated for oesophageal cancer?

Voorde

Janssen

Larue

et al. 2015

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

show abstract

“…Moreover, diabetic and cardiovascular disease patients who are prescribed metformin have increased rates of survival (Scarpello 2003;Yin et al 2013), and it was recently proposed that metformin might promote longevity by preventing frailty in older adults with T2DM (Wang et al 2014). Chronic treatment with metformin among patients with diabetes might reduce the risk of cognitive decline and dementia (Ng et al 2014;Patrone et al 2014) and improve survival in several types of cancer (Greenhill 2015;Ko et al 2015;Lin et al 2015;Rego et al 2015).…”

Section: Metformin As An Anti-aging Drugmentioning

confidence: 99%

Metformin: A Hopeful Promise in Aging Research

Novelle

Ali

Diéguez

et al. 2016

Cold Spring Harb Perspect Med

124

View full text Add to dashboard Cite

Even though the inevitable process of aging by itself cannot be considered a disease, it is directly linked to life span and is the driving force behind all age-related diseases. It is an undisputable fact that age-associated diseases are among the leading causes of death in the world, primarily in industrialized countries. During the last several years, an intensive search of antiaging treatments has led to the discovery of a variety of drugs that promote health span and/or life extension. The biguanide compound metformin is widely used for treating people with type 2 diabetes and appears to show protection against cancer, inflammation, and agerelated pathologies. Here, we summarize the recent developments about metformin use in translational aging research and discuss its role as a potential geroprotector.

show abstract

“…Wirkung und auch eine Reduktion der lokoregionalen Rezidivrate mit verbessertem Gesamtüberleben zugeschrieben [8,11,16,21,29] …”

unclassified

Diabetes mellitus als prognostischer Marker beim Oropharynx- und Larynxkarzinom

Zaoui

Doll

Stiebi

et al. 2016

HNO

View full text Add to dashboard Cite

Recent experimental and clinical studies have provided compelling evidence that diabetes mellitus (DM) is an important risk factor in various cancers, and may affect both pathogenesis and prognosis. Additionally, antidiabetic agents such as metformin exhibit an antitumorigenic effect. However, to date there is insufficient knowledge about the role of DM in the pathogenesis and prognosis of head and neck squamous cell carcinoma (HNSCC).In a retrospective monocentric study including 424 patients with SCC of the oropharynx (OPSCC) or larynx (LaSCC), the impact of DM on clinical and histopathologic parameters was investigated. The authors found a rising incidence of DM among LaSCC patients (<10 % until 2005 and 20 % since 2006) and a significant association between DM and clinical and histopathologic features (age, gender, tumor size, and pathologic grading), which depended on the anatomic site. Moreover, a clear trend toward unfavorable progression-free and overall survival of HNSCC patients with DM upon current treatment modalities was evident.The presented data support a relative increase in patients with DM, particularly for LaSCC. This might have a sustained influence on treatment decisions and management, and should be considered in future clinical trials. A better understanding of the cellular and molecular traits of HNSCC in DM could pave the way for innovative therapeutic strategies in terms of personalized medicine.

show abstract

Effects of metformin on head and neck cancer: A systematic review

Cited by 68 publications

References 58 publications

Can metformin improve ‘the tomorrow’ of patients treated for oesophageal cancer?

Can metformin improve ‘the tomorrow’ of patients treated for oesophageal cancer?

Metformin: A Hopeful Promise in Aging Research

Diabetes mellitus als prognostischer Marker beim Oropharynx- und Larynxkarzinom

Contact Info

Product

Resources

About